Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-06-01
2002-03-26
Reamer, James H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06362194
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a method of enhancing the analgesic (inhibitory) effects of bimodally-acting opioid agonists, including morphine, codeine and other-clinically used opioid analgesics, while at the same time attenuating anti-analgesia, physical dependence, tolerance, hyperexcitability, hyperalgesia, and other undesirable (excitatory) side effects typically caused by chronic use of bimodally-acting opioid agonists.
“Bimodally-acting opioid agonists” are opioid agonists that bind to and activate both inhibitory and excitatory opioid receptors on nociceptive neurons which mediate pain. Opioid analgesia results from activation by opioid agonists of inhibitory opioid receptors on neurons in the nociceptive (pain) pathways of the peripheral and central nervous systems. The undesirable side effects, including anti-analgesic actions, hyperexcitability and hyperalgesia, the development of physical dependence, and some types of tolerance result from sustained activation by bimodally-acting opioid agonists of excitatory opioid receptors on neurons in the nociceptive (pain) pathways of the peripheral and central nervous systems.
In the instant invention, a very low dose of a selective excitatory opioid receptor antagonist, an opioid which binds to and acts as an antagonist to excitatory but not inhibitory opioid receptors on nociceptive neurons which mediate pain, is combined with a dose of a bimodally-acting opioid agonist so as to enhance the degree of analgesia (inhibitory effects) and attenuate the undesired side effects (excitatory effects).
BACKGROUND OF THE INVENTION
Morphine or other bimodally-acting opioid agonists are administered to relieve severe pain due to the fact that they have analgesic effects mediated by their activation of inhibitory opioid receptors on nociceptive neurons (see North,
Trends Neurosci.,
Vol. 9, pp. 114-117 (1986) and Crain and Shen,
Trends Pharmacol.
Sci., Vol. 11, pp. 77-81 (1990)).
However, morphine and other bimodally-acting opioid agonists also activate opioid excitatory receptors on nociceptive neurons, which attenuate the analgesic potency of the opioids and result in the development of physical dependence and increased tolerance (see Shen and Crain,
Brain Res.,
Vol. 597, pp. 74-83 (1992)), as well as hyperexcitability, hyperalgesia and other undesirable (excitatory) side effects. As a result, a long-standing need has existed to develop a method of both enhancing the analgesic (inhibitory) effects of bimodally-acting opioid agonists and blocking or preventing undesirable (excitatory) side effects caused by such opioid agonists. The present invention satisfies this need.
SUMMARY OF THE INVENTION
This present invention is directed to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of the bimodally-acting opioid agonist. The method comprises administering to a subject an analgesic or sub-analgesic amount of a bimodally-acting opioid agonist and an amount of an excitatory opioid receptor antagonist effective to enhance the analgesic potency of the bimodally-acting opioid agonist and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of the bimodally-acting opioid agonist.
The present invention also provides a method for treating pain in a subject comprising administering to the subject an analgesic or sub-analgesic amount of a bimodally-acting opioid agonist and an amount of an excitatory opioid receptor antagonist effective to enhance the analgesic potency of the bimodally-acting opioid agonist and attenuate anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance-effects of the bimodally-acting opioid agonist.
The present invention further provides a method for treating an opiate addict comprising administering to the opiate addict an amount of an excitatory opioid receptor antagonist either alone or in combination with a bimodally-acting opioid agonist effective to attenuate physical dependence caused by a bimodally-acting opioid agonist and enhance the analgesic potency of a bimodally-acting opioid agonist.
Finally, the present invention provides a composition comprising an analgesic or sub-analgesic amount of a bimodally-acting opioid agonist and an amount of an excitatory opioid receptor antagonist effective to enhance the analgesic potency of the bimodally-acting opioid agonist and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of the bimodally-acting opioid agonist in a subject administered the composition.
REFERENCES:
patent: 3332950 (1967-07-01), Blumberg et al.
patent: 4361553 (1982-11-01), Loh et al.
patent: 4457933 (1984-07-01), Gordon et al.
patent: 4760069 (1988-07-01), Rezeszotarski et al.
patent: 4769372 (1988-09-01), Kreek
patent: 4882335 (1989-11-01), Sinclair
patent: 4889860 (1989-12-01), Rezeszotarski et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5086058 (1992-02-01), Sinclair
patent: 5096715 (1992-03-01), Sinclair
patent: 5317022 (1994-05-01), Borsodi et al.
patent: 5321012 (1994-06-01), Mayer et al.
patent: 5352680 (1994-10-01), Portoghese et al.
patent: 85/50585 (1986-06-01), None
patent: 88/26432 (1989-06-01), None
patent: 88/18970 (1990-01-01), None
patent: 92/24023 (1993-02-01), None
patent: 144243 (1985-06-01), None
patent: 319243 (1989-06-01), None
patent: 352361 (1990-01-01), None
patent: 415693 (1991-03-01), None
patent: WO87/01703 (1987-03-01), None
patent: WO94/06426 (1994-03-01), None
patent: 9406426 (1994-03-01), None
patent: WO95/03804 (1995-02-01), None
patent: 9503804 (1995-09-01), None
Datta, et al., Peptides, vol. 3, pp. 433-437, 1992.
Tremblay, et al., Psychopharmacology, vol. 49, pp. 41-48, 1976.
Shen and Crain, Brain Research, vol. 636, pp. 286-291, 1994.
Berkow, Robert et al., The Merck Manual of Diagnosis and Therapy, 16th Edition, Merck & Co. Inc., NY 1992 pp. 1558-1559.
Reynolds, JEF Martindale, The Extra Pharmacopoeica, 30th Ed., The Pharmaceutical Press, London, 1993, pp. 687-688.
Shen and Crain,Regulatory Peptides, in press (1993).
Shen and Crain,Brain Research, 597:74-83 (1992).
Shen and Crain,Brain Research, 575:13-24 (1992).
Wang, et al.,Chinese J. Pharm. Toxicol., 6:36-40 (1992) and English translation thereof.
Bo-Yi, Quin,New Drugs and Clinical Remedies, 12:119-123 (1992) and English translation thereof.
Lange, et al.,Toxicol. Applied Pharm., 54:177-186 (1980).
Terwillinger, et al.,Brain Research, 548:100-110 (1991).
Shen, et al.,Brain Research, 559:130-138 (1991).
Crain and Shen,Trends Pharmacol. Sci., 11:77-81 (1990).
Fujimoto, et al.,Neuropharmacol., 29:609-617 (1990).
Shen and Crain,Brain Research, 531:1-7 (1990).
Shen and Crain,Brain Research, 491:227-242 (1989).
North,Trends Neurosci., 9:114-117 (1986).
Magnan, et al.,Nauyn-Schmiedelberg's Arch. Pharmacol., 319:197-205 (1982).
Bentley and Hardy,J. American Chem. Soc., 89:3281-3286 (1967).
Bentley and Hardy,Proc. Chem. Soc., p. 220 (1963).
Holmes and Fujimoto,Anesth. Analg., 77:1166-1173 (1993).
Miaskowski and Levine,Brain Research, 596:41-45 (1992).
Vaccarino, et al.,Pain, 36:103-109 (1989).
Cappell, et al.,Pharmacology Biochemistry&Behavior, 34:425-427 (1989).
Gardner,Substance Abuse, 2d ed., pp. 70-99 (1992).
Shen and Crain,Brain Res., 636:286-297 (1994).
Greenstein, et al.,Subst. A buse, 2d ed., pp. 562-573 (1992).
Gonzales, et al.,Drugs, 35:193-213 (1988).
Shen and Crain,J. Neurosci., 14:5570-5579 (1994).
Blane, et al.,Brit. J. Pharmacol. Chemother., 30:11-22 (1967).
Fujimoto, et al.,J. Pharm. Exp. Ther., 251:1045-1052 (1989).
Gillman, et al.,Intern. J. Neurosci., 48:321-324 (1989).
Gillman, et al.,J. Neurol. Sciences, 49:41-49 (1981).
Gillman, et al.,South African J. Science, 83:560-563 (1987).
Pederson, et al.,Brit. J. Anaesth., 57:1045-1046 (1985).
Schmidt, et al.,Anesthesia, 40:583-586 (1985).
Bergman, et al.,Arch. Int. Pharmac
Crain Stanley M.
Shen Ke-fei
Albert Einstein College of Medicine of Yeshiva University
Amster Rothstein & Ebenstein
Reamer James H.
LandOfFree
Method and simultaneously enhancing analgesic potency and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and simultaneously enhancing analgesic potency and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and simultaneously enhancing analgesic potency and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2882500